Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery

Trial Profile

A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Omeprazole (Primary)
  • Indications Cardiovascular disorders; Embolism and thrombosis; Gastrointestinal haemorrhage; Myocardial disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MANAGE
  • Most Recent Events

    • 02 Feb 2019 This trial has been completed in United Kingdom, according to the European Clinical Trials Database record.
    • 16 Oct 2018 Results published in the Annals of Internal Medicine
    • 22 Mar 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top